{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:55:10Z","timestamp":1780520110037,"version":"3.54.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2022.10.060","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:51:09Z","timestamp":1668646269000},"page":"A142-A152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S1","title":["Outbreak response strategies with type 2-containing oral poliovirus vaccines"],"prefix":"10.1016","volume":"41","author":[{"given":"Dominika A.","family":"Kalkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.F.","family":"Wassilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Durry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Badizadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-9147","authenticated-orcid":false,"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2022.10.060_b0005","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Tebbens","year":"2006","journal-title":"Risk Anal"},{"issue":"6","key":"10.1016\/j.vaccine.2022.10.060_b0010","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1539-6924.2006.00831.x","article-title":"Retrospective cost-effectiveness analyses for polio vaccination in the United States","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.060_b0015","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/risa.12022","article-title":"Review: Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2022.10.060_b0020","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1017\/S095026881900181X","article-title":"Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters","volume":"147","author":"Kalkowska","year":"2019","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2022.10.060_b0025","unstructured":"World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame Strategic Plan (2013-2018). http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/PEESP_EN_A4.pdf; 2013 [accessed Jun 4, 2019]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000\u20132019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.060_b0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/erv.11.195","article-title":"Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation","volume":"11","author":"Thompson","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"35","key":"10.1016\/j.vaccine.2022.10.060_b0040","first-page":"934","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2022.10.060_b0045","first-page":"190","article-title":"The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation","volume":"10","author":"Thompson","year":"2008","journal-title":"Med J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.10.060_b0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14760584.2017.1322514","article-title":"Poliovirus vaccination during the endgame: Insights from integrated modeling","volume":"16","author":"Duintjer Tebbens","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.10.060_b0055","first-page":"681","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"issue":"20","key":"10.1016\/j.vaccine.2022.10.060_b0060","doi-asserted-by":"crossref","first-page":"538","DOI":"10.15585\/mmwr.mm6620a4","article-title":"Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016\u20132017","volume":"66","author":"Diop","year":"2017","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.10.060_b0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(21)00453-9","article-title":"Risk factors for spread of vaccine-derived type 2 polioviruses in Africa following global withdrawal of trivalent oral poliovirus vaccine and impact of outbreak response with monovalent vaccine: a retrospective analysis of surveillance data","volume":"22","author":"Cooper","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.060_b0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(21)00458-8","article-title":"Polio eradication: what kind of world do we want?","volume":"22","author":"Thompson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6489","key":"10.1016\/j.vaccine.2022.10.060_b0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.060_b0080","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2022.10.060_b0085","unstructured":"World Health Organization Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/09\/weekly-polio-analyses-cVDPV-20220906.pdf; 2022 [accessed 9 Sep, 2022]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0090","first-page":"301","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2017 - conclusions and recommendations","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2022.10.060_b0095","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1093\/infdis\/jit838","article-title":"Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation","volume":"210","author":"Duintjer Tebbens","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of poliovirus outbreak response strategies for 2019\u20132029: Impacts of the use of novel OPV2 strains","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2022.10.060_b0105","doi-asserted-by":"crossref","unstructured":"Harutyunyan V QA, Pallansch M, Zipursky S, Woods D, Ottosen A, Vertefeuille J, Lewis I. Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal. Vaccine. 2022; S0264-410X(22)00204-3.","DOI":"10.1016\/j.vaccine.2022.02.058"},{"key":"10.1016\/j.vaccine.2022.10.060_b0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infecti Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.10.060_b0115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Duintjer Tebbens","year":"2018","journal-title":"Risk Anal"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.060_b0120","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-015-1116-4","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission","volume":"15","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0125","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/infdis\/jiab160","article-title":"Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response options","volume":"224","author":"Kalkowska","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0130","article-title":"Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response","author":"Kalkowska","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.10.060_b0135","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1539-6924.2006.00843.x","article-title":"Evaluation of response scenarios to potential polio outbreaks using mathematical models","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.060_b0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-015-1112-8","article-title":"An economic analysis of poliovirus risk management policy options for 2013\u20132052","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0145","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jix128","article-title":"Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/risa.13447","article-title":"Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"issue":"17","key":"10.1016\/j.vaccine.2022.10.060_b0155","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1128\/JVI.00370-06","article-title":"Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication","volume":"80","author":"Macadam","year":"2006","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.060_b0160","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.10.060_b0165","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2217\/fmb-2016-0126","article-title":"The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management","volume":"11","author":"Duintjer Tebbens","year":"2016","journal-title":"Future Microbiol"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.10.060_b0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"S\u00e1ez-Llorens","year":"2021","journal-title":"The Lancet"},{"issue":"10268","key":"10.1016\/j.vaccine.2022.10.060_b0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials","volume":"397","author":"De Coster","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2022.10.060_b0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-020-0176-7","article-title":"Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization","volume":"5","author":"Konopka-Anstadt","year":"2020","journal-title":"npj Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.060_b0185","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/jiab507","article-title":"Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV\/IPV-vaccinated infants: two randomized clinical trials","volume":"226","author":"Gast","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0190","unstructured":"World Health Organization. cVDPV2 outbreaks and the type 2 novel oral poliovirus vaccine (nOPV2). https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/01\/GPEI_cVDPV2-nOPV2_Factsheet_13-Jan-2022-EN.pdf; 2022 [accessed Feb 24, 2022]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0195","first-page":"17","article-title":"Global Advisory Committee on Vaccine Safety, 17 September 2021","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2022.10.060_b0200","unstructured":"Global Polio Eradication Initiative. nOPV2: Clinical development summary updated June 2022. https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/06\/nOPV2-Clinical-Development-Summary_June-2022-Update_Final-EN.pdf; 2022 [accessed 11 Aug 2022]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0205","first-page":"613","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2021: conclusions and recommendations","volume":"96","author":"World Health Organization","year":"2021","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2022.10.060_b0210","unstructured":"Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, et al. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine. 2021:S0264-410X(21)00473-4."},{"key":"10.1016\/j.vaccine.2022.10.060_b0215","unstructured":"World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Part 2: Protocol for poliovirus type 2. http:\/\/polioeradication.org\/wp-content\/uploads\/2018\/01\/pol-sop-responding-polio-event-outbreak-part2-20180117.pdf; 2018 [accessed August 20, 2020]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0220","unstructured":"World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Version 3.1, March 2020. http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/POL-SOP-V3.1-20200424.pdf; 2020 [accessed August 20, 2020]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0225","unstructured":"World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2019-2023). https:\/\/polioeradication.org\/wp-content\/uploads\/2019\/06\/english-polio-endgame-strategy.pdf; 2019 [accessed Jun 4, 2019]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0230","unstructured":"World Health Organization Global Polio Eradication Initiative. Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020\u20132021: Addendum to the Polio eradication and endgame strategic plan (2019-2023). http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf; 2020 [accessed Mar 10, 2020]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0235","unstructured":"World Health Organization Global Polio Eradication Initiative. Polio eradication strategy 2022-2026: Delivering on a promise. https:\/\/polioeradication.org\/wp-content\/uploads\/2021\/06\/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf; 2021 [accessed Jun 11, 2021]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0240","unstructured":"World Health Organization. WHO\/UNICEF estimated coverage time series. http:\/\/www.who.int\/entity\/immunization\/monitoring_surveillance\/data\/coverage_estimates_series.xls; 2020 [accessed Jul 24, 2020]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0245","article-title":"Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan","author":"Kalkowska","year":"2022","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2022.10.060_b0250","unstructured":"World Health Organization. Wild poliovirus list: List of wild poliovirus by country and year. https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/09\/weekly-polio-analyses-WPV-20220906.pdf; 2022 [accessed 9 Sep, 2022]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0255","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2018.1506333","article-title":"Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine","volume":"17","author":"Duintjer Tebbens","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.10.060_b0260","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.10.060_b0265","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1016\/j.vaccine.2010.04.001","article-title":"Optimal vaccine stockpile design for an eradicated disease: Application to polio","volume":"28","author":"Duintjer Tebbens","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.060_b0270","unstructured":"World Health Organization Global Polio Eradication Initiative. Standard operating procedures - Responding to a poliovirus event or outbreak - version 4. https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/07\/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220807-EN-Final.pdf; 2022 [accessed 20 Aug, 2022]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0275","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/infdis\/jiab518","article-title":"Time taken to detect and respond to polio outbreaks in Africa and the potential impact of direct molecular detection and nanopore sequencing","volume":"226","author":"Shaw","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0280","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coviro.2013.05.007","article-title":"Poliovirus vaccination options for achieving eradication and securing the endgame","volume":"3","author":"Estivariz","year":"2013","journal-title":"Current Opinion in Virology"},{"key":"10.1016\/j.vaccine.2022.10.060_b0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-016-1537-8","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0290","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-016-1536-9","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.060_b0295","unstructured":"World Health Organization Global Polio Eradication Initiative. GPEI statement on WPV1 in Malawi. https:\/\/polioeradication.org\/news-post\/gpei-statement-on-wpv1-in-malawi\/; 2022 [accessed Feb 22, 2022]."},{"key":"10.1016\/j.vaccine.2022.10.060_b0300","first-page":"340","article-title":"Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation","volume":"7","author":"Duintjer Tebbens","year":"2016","journal-title":"J Vaccines Vaccination"},{"key":"10.1016\/j.vaccine.2022.10.060_b0305","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/risa.13590","article-title":"Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2022.10.060_b0310","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.vaccine.2015.02.013","article-title":"Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses","volume":"33","author":"Thompson","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:17Z","timestamp":1759404317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":62,"alternative-id":["S0264410X22013366"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outbreak response strategies with type 2-containing oral poliovirus vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}